Bristol Myers Squibb Reports CheckMate-274 Data for Opdivo in Muscle-Invasive Bladder Cancer

Bristol Myers Squibb today presented updated data from the Phase 3 CheckMate-274 trial evaluating adjuvant Opdivo (nivolumab) in patients with high-risk muscle-invasive urothelial carcinoma following radical resection. The updated data showed that the disease-free survival benefit of Opdivo was maintained over long-term follow-up, with a 30% reduction in the risk of disease recurrence or death.